कृपया अन्य खोज का प्रयास करें
Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Jeffrey Crawford | - | - | Chairman of Scientific Advisory Board |
David Grdina | - | - | Member of Scientific Advisory Board |
Frank Castellana | - | 2022 | Member of Corporate Advisory Committee |
Ki-Young Sohn | - | - | Chairman & Chief Executive Officer |
John Choi | - | - | Executive Director |
Hye-Kyung Kim | - | - | Vice Chairman |
Jong-Koo Kang | 69 | 2017 | Director |
Alexander Fleming | - | 2022 | Member of Corporate Advisory Committee & CTO |
Sang-Gon Ko | 71 | 2017 | Director |
Sang-Hee Kim | 89 | 2017 | Director |
Jae-Yong Lee | - | - | VP & Executive Director |
Jae-Wha Kim | - | - | Member of Scientific Advisory Board |
Do-Young Lee | - | - | Chief Scientific Officer & Member of the Board of Directors |
Stephen T. Sonis | - | - | Member of Scientific Advisory Board |
Larry W. Kwak | - | - | Member of Scientific Advisory Board |
Cecil Czerkinsky | - | - | Member of Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है